Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $20.00.

ABEO has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $5.04 on Wednesday. Abeona Therapeutics has a 1-year low of $3.93 and a 1-year high of $7.54. The company has a 50 day moving average of $5.19 and a 200-day moving average of $5.47. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. The firm has a market cap of $273.12 million, a price-to-earnings ratio of 4.10 and a beta of 1.18.

Insider Activity at Abeona Therapeutics

In other Abeona Therapeutics news, CFO Joseph Walter Vazzano sold 18,666 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total value of $99,489.78. Following the transaction, the chief financial officer directly owned 568,560 shares in the company, valued at approximately $3,030,424.80. This trade represents a 3.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vishwas Seshadri sold 69,832 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total value of $372,204.56. Following the sale, the chief executive officer owned 1,460,408 shares of the company’s stock, valued at approximately $7,783,974.64. The trade was a 4.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 209,605 shares of company stock valued at $1,101,300 in the last three months. 5.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Abeona Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. J. Goldman & Co LP acquired a new position in Abeona Therapeutics during the 4th quarter valued at about $2,102,000. AQR Capital Management LLC raised its stake in shares of Abeona Therapeutics by 240.7% during the fourth quarter. AQR Capital Management LLC now owns 114,520 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 80,908 shares during the last quarter. Cetera Investment Advisers acquired a new position in Abeona Therapeutics in the fourth quarter valued at approximately $96,000. Jain Global LLC bought a new position in Abeona Therapeutics in the fourth quarter valued at approximately $1,929,000. Finally, Jump Financial LLC acquired a new stake in Abeona Therapeutics during the 4th quarter worth $400,000. 80.56% of the stock is owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.